OTCMKTS:OTLC Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free OTLC Stock Alerts $0.04 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.01▼$0.05Volume58,266 shsAverage Volume63,606 shsMarket Capitalization$14.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Oncotelic Therapeutics alerts: Email Address Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.Read More OTLC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLC Stock News HeadlinesMay 16 at 3:57 AM | finance.yahoo.comONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024March 25, 2024 | finance.yahoo.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 25, 2024 | globenewswire.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 4, 2024 | globenewswire.comInvitation to Participate in STOP-PC Clinical TrialFebruary 22, 2024 | benzinga.comOncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning CallsFebruary 3, 2024 | msn.comOncotelic Therapeutics Strikes Material Definitive Legal AgreementJanuary 23, 2024 | morningstar.comLineage Cell Therapeutics Inc LCTXDecember 18, 2023 | finance.yahoo.comOncotelic Therapeutics Announces Opening of GMP Manufacturing PlantNovember 15, 2023 | finanznachrichten.deOncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsNovember 15, 2023 | msn.comOncotelic Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comOncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The ChargeSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The ChargeAugust 25, 2023 | finance.yahoo.comOncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023August 23, 2023 | finance.yahoo.comSapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic CancerMay 16, 2023 | finance.yahoo.comOncotelic Participating at 2023 BIO International ConventionApril 24, 2023 | technews.tmcnet.comOncotelic Launches PDAO SEC ChatbotApril 20, 2023 | seekingalpha.comOncotelic Therapeutics reports FY resultsApril 19, 2023 | finance.yahoo.comOncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model TechnologyMarch 13, 2023 | technews.tmcnet.comHigh Intra-Tumor TGF-ß2 Predicts Poor Survival in Pediatric Cancer of the BrainstemFebruary 15, 2023 | seekingalpha.comOTLC Oncotelic Therapeutics, Inc.February 6, 2023 | finance.yahoo.comOncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell CancerJanuary 25, 2023 | finance.yahoo.comOncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerDecember 28, 2022 | finance.yahoo.comOncotelic Issues Year End Message to ShareholdersNovember 8, 2022 | finance.yahoo.comOncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric GliomasSee More Headlines Receive OTLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/19/2021Today5/16/2024Next Earnings (Estimated)5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OTLC CUSIPN/A CIK908259 Webwww.mateon.com Phone(650) 635-7000Fax650-635-7001Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,900,000.00 Net MarginsN/A Pretax Margin-11,722.86% Return on Equity-57.94% Return on Assets-24.83% Debt Debt-to-Equity Ratio0.16 Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual Sales$70,000.00 Price / Sales205.03 Cash Flow$0.01 per share Price / Cash Flow3.03 Book Value$0.03 per share Price / Book1.20Miscellaneous Outstanding Shares398,670,000Free Float242,309,000Market Cap$14.35 million OptionableNot Optionable Beta0.03 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Vuong Trieu Ph.D. (Age 61)Chairman & CEO Mr. Amit Shah (Age 57)Chief Financial Officer Dr. Anthony E. Maida III (Age 72)B.A., MA, MBA, Ph.D., Chief Medical Officer Translation Medicine & Director Mr. Saranjit Saund (Age 66)CBO & GM of AI Division Mr. Steven W. King (Age 60)Consultant & Director Dr. Larn Hwang (Age 61)Chief Scientific Officer Dr. Seymour Howard Fein M.D. (Age 75)Chief Regulatory Officer & Chief Medical Officer Mr. Burcak BeserCTO of AI DivisionMore ExecutivesKey CompetitorsNeuroSense TherapeuticsNASDAQ:NRSNTonix PharmaceuticalsNASDAQ:TNXPCeaproOTCMKTS:CRPOFSynthetic BiologicsNYSEAMERICAN:SYNVincerx PharmaNASDAQ:VINCView All Competitors OTLC Stock Analysis - Frequently Asked Questions How have OTLC shares performed in 2024? Oncotelic Therapeutics' stock was trading at $0.0383 at the start of the year. Since then, OTLC stock has decreased by 6.0% and is now trading at $0.0360. View the best growth stocks for 2024 here. Are investors shorting Oncotelic Therapeutics? Oncotelic Therapeutics saw a decrease in short interest in April. As of April 30th, there was short interest totaling 1,800 shares, a decrease of 84.2% from the April 15th total of 11,400 shares. Based on an average daily trading volume, of 68,700 shares, the days-to-cover ratio is currently 0.0 days. View Oncotelic Therapeutics' Short Interest. When is Oncotelic Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024. View our OTLC earnings forecast. How were Oncotelic Therapeutics' earnings last quarter? Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) announced its quarterly earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. How do I buy shares of Oncotelic Therapeutics? Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OTLC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.